Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study

F. Morisco, S. Camera, M. Guarino, R. Tortora, V. Cossiga, A. Vitiello, G. Cordone, N. Caporaso, G.G. Di Costanzo, M. Zoli, F. Garuti, A. Neri, F. Piscaglia, B. Lenzi, M. Valente, F. Trevisani, L. Bolondi, M. Biselli, P. Caraceni, A. CucchettiM. Domenicali, A. Gramenzi, D. Magalotti, C. Serra, L. Venerandi, A. Cappelli, R. Golfieri, C. Mosconi, M. Renzulli, E.G. Giannini, M. Brunacci, A. Moscatelli, G. Pellegatta, V. Savarino, E. Caturelli, P. Roselli, V. Lauria, G. Pelecca, S. Dell'Isola, A.M. Ialungo, E. Rastrelli, G. Cabibbo, C. Cammà, S. Attardo, M. Rossi, G.L. Rapaccini, A. Gasbarrini, G. Cavani, R. Virdone, A. Affronti

Research output: Contribution to journalArticle

Abstract

Background:Limited therapies are available for large (≥40 mm) unresectable hepatocellular carcinoma (HCC). Currently, the standard treatment with transarterial chemoembolisation (TACE) is unsatisfactory with high recurrence rate and limited effect on survival. Laser Ablation (LA) has emerged as a relatively new technique characterized by high efficacy and good safety. This study is aimed to evaluate the efficacy of LA in comparison to TACE in patients with large HCC. Methods: Eighty-two patients with a single HCC nodule ≥40 mm (BCLC stage A or B) were enrolled in this case-control study. Forty-one patients were treated with LA and 41 patients were treated with TACE. Response to therapy was evaluated according to the mRECIST criteria. Survival was calculated with Kaplan-Meier from the time of cancer diagnosis to death with values censored at the date of the last follow-up. Results: Twenty-six (63.4%) and 8 (19.5%) patients had a complete response after LA and TACE, respectively (p <0.001). Subsequently we stratified the HCCs in 3 categories according to the nodule size: 40-50 mm, 51-60 mm, and > 60 mm. LA resulted superior to TACE especially in nodules ranging between 51 and 60 mm in diameter, with a complete response rate post-LA and post-TACE of 75% and 14.3%, respectively (p = 0.0133). The 36 months cumulative survival rate in patients treated with LA and TACE was 55.4% and 48.8%, respectively. The disease recurrence rates after LA and TACE were 19.5% and 75.0%, respectively. Conclusions: LA is a more effective therapeutic option than TACE in patients with solitary large HCC. © Morisco et al.
Original languageEnglish
Pages (from-to)17483-17490
Number of pages8
JournalOncotarget
Volume9
Issue number25
DOIs
Publication statusPublished - 2018

Fingerprint

Laser Therapy
Case-Control Studies
Hepatocellular Carcinoma
Recurrence
Survival
Therapeutics
Survival Rate
Safety

Keywords

  • aged
  • Article
  • cancer diagnosis
  • cancer recurrence
  • cancer survival
  • case control study
  • chemoembolization
  • clinical feature
  • controlled study
  • disease free survival
  • drug efficacy
  • drug safety
  • human
  • Kaplan Meier method
  • laser surgery
  • liver cell carcinoma
  • major clinical study
  • retrospective study
  • survival rate
  • treatment response
  • univariate analysis

Cite this

Morisco, F., Camera, S., Guarino, M., Tortora, R., Cossiga, V., Vitiello, A., ... Affronti, A. (2018). Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study. Oncotarget, 9(25), 17483-17490. https://doi.org/10.18632/oncotarget.24756

Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study. / Morisco, F.; Camera, S.; Guarino, M.; Tortora, R.; Cossiga, V.; Vitiello, A.; Cordone, G.; Caporaso, N.; Di Costanzo, G.G.; Zoli, M.; Garuti, F.; Neri, A.; Piscaglia, F.; Lenzi, B.; Valente, M.; Trevisani, F.; Bolondi, L.; Biselli, M.; Caraceni, P.; Cucchetti, A.; Domenicali, M.; Gramenzi, A.; Magalotti, D.; Serra, C.; Venerandi, L.; Cappelli, A.; Golfieri, R.; Mosconi, C.; Renzulli, M.; Giannini, E.G.; Brunacci, M.; Moscatelli, A.; Pellegatta, G.; Savarino, V.; Caturelli, E.; Roselli, P.; Lauria, V.; Pelecca, G.; Dell'Isola, S.; Ialungo, A.M.; Rastrelli, E.; Cabibbo, G.; Cammà, C.; Attardo, S.; Rossi, M.; Rapaccini, G.L.; Gasbarrini, A.; Cavani, G.; Virdone, R.; Affronti, A.

In: Oncotarget, Vol. 9, No. 25, 2018, p. 17483-17490.

Research output: Contribution to journalArticle

Morisco, F, Camera, S, Guarino, M, Tortora, R, Cossiga, V, Vitiello, A, Cordone, G, Caporaso, N, Di Costanzo, GG, Zoli, M, Garuti, F, Neri, A, Piscaglia, F, Lenzi, B, Valente, M, Trevisani, F, Bolondi, L, Biselli, M, Caraceni, P, Cucchetti, A, Domenicali, M, Gramenzi, A, Magalotti, D, Serra, C, Venerandi, L, Cappelli, A, Golfieri, R, Mosconi, C, Renzulli, M, Giannini, EG, Brunacci, M, Moscatelli, A, Pellegatta, G, Savarino, V, Caturelli, E, Roselli, P, Lauria, V, Pelecca, G, Dell'Isola, S, Ialungo, AM, Rastrelli, E, Cabibbo, G, Cammà, C, Attardo, S, Rossi, M, Rapaccini, GL, Gasbarrini, A, Cavani, G, Virdone, R & Affronti, A 2018, 'Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study', Oncotarget, vol. 9, no. 25, pp. 17483-17490. https://doi.org/10.18632/oncotarget.24756
Morisco, F. ; Camera, S. ; Guarino, M. ; Tortora, R. ; Cossiga, V. ; Vitiello, A. ; Cordone, G. ; Caporaso, N. ; Di Costanzo, G.G. ; Zoli, M. ; Garuti, F. ; Neri, A. ; Piscaglia, F. ; Lenzi, B. ; Valente, M. ; Trevisani, F. ; Bolondi, L. ; Biselli, M. ; Caraceni, P. ; Cucchetti, A. ; Domenicali, M. ; Gramenzi, A. ; Magalotti, D. ; Serra, C. ; Venerandi, L. ; Cappelli, A. ; Golfieri, R. ; Mosconi, C. ; Renzulli, M. ; Giannini, E.G. ; Brunacci, M. ; Moscatelli, A. ; Pellegatta, G. ; Savarino, V. ; Caturelli, E. ; Roselli, P. ; Lauria, V. ; Pelecca, G. ; Dell'Isola, S. ; Ialungo, A.M. ; Rastrelli, E. ; Cabibbo, G. ; Cammà, C. ; Attardo, S. ; Rossi, M. ; Rapaccini, G.L. ; Gasbarrini, A. ; Cavani, G. ; Virdone, R. ; Affronti, A. / Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study. In: Oncotarget. 2018 ; Vol. 9, No. 25. pp. 17483-17490.
@article{befd64c86c474ca5ba6055c6ab4d60b3,
title = "Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study",
abstract = "Background:Limited therapies are available for large (≥40 mm) unresectable hepatocellular carcinoma (HCC). Currently, the standard treatment with transarterial chemoembolisation (TACE) is unsatisfactory with high recurrence rate and limited effect on survival. Laser Ablation (LA) has emerged as a relatively new technique characterized by high efficacy and good safety. This study is aimed to evaluate the efficacy of LA in comparison to TACE in patients with large HCC. Methods: Eighty-two patients with a single HCC nodule ≥40 mm (BCLC stage A or B) were enrolled in this case-control study. Forty-one patients were treated with LA and 41 patients were treated with TACE. Response to therapy was evaluated according to the mRECIST criteria. Survival was calculated with Kaplan-Meier from the time of cancer diagnosis to death with values censored at the date of the last follow-up. Results: Twenty-six (63.4{\%}) and 8 (19.5{\%}) patients had a complete response after LA and TACE, respectively (p <0.001). Subsequently we stratified the HCCs in 3 categories according to the nodule size: 40-50 mm, 51-60 mm, and > 60 mm. LA resulted superior to TACE especially in nodules ranging between 51 and 60 mm in diameter, with a complete response rate post-LA and post-TACE of 75{\%} and 14.3{\%}, respectively (p = 0.0133). The 36 months cumulative survival rate in patients treated with LA and TACE was 55.4{\%} and 48.8{\%}, respectively. The disease recurrence rates after LA and TACE were 19.5{\%} and 75.0{\%}, respectively. Conclusions: LA is a more effective therapeutic option than TACE in patients with solitary large HCC. {\circledC} Morisco et al.",
keywords = "aged, Article, cancer diagnosis, cancer recurrence, cancer survival, case control study, chemoembolization, clinical feature, controlled study, disease free survival, drug efficacy, drug safety, human, Kaplan Meier method, laser surgery, liver cell carcinoma, major clinical study, retrospective study, survival rate, treatment response, univariate analysis",
author = "F. Morisco and S. Camera and M. Guarino and R. Tortora and V. Cossiga and A. Vitiello and G. Cordone and N. Caporaso and {Di Costanzo}, G.G. and M. Zoli and F. Garuti and A. Neri and F. Piscaglia and B. Lenzi and M. Valente and F. Trevisani and L. Bolondi and M. Biselli and P. Caraceni and A. Cucchetti and M. Domenicali and A. Gramenzi and D. Magalotti and C. Serra and L. Venerandi and A. Cappelli and R. Golfieri and C. Mosconi and M. Renzulli and E.G. Giannini and M. Brunacci and A. Moscatelli and G. Pellegatta and V. Savarino and E. Caturelli and P. Roselli and V. Lauria and G. Pelecca and S. Dell'Isola and A.M. Ialungo and E. Rastrelli and G. Cabibbo and C. Camm{\`a} and S. Attardo and M. Rossi and G.L. Rapaccini and A. Gasbarrini and G. Cavani and R. Virdone and A. Affronti",
note = "cited By 0",
year = "2018",
doi = "10.18632/oncotarget.24756",
language = "English",
volume = "9",
pages = "17483--17490",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "25",

}

TY - JOUR

T1 - Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study

AU - Morisco, F.

AU - Camera, S.

AU - Guarino, M.

AU - Tortora, R.

AU - Cossiga, V.

AU - Vitiello, A.

AU - Cordone, G.

AU - Caporaso, N.

AU - Di Costanzo, G.G.

AU - Zoli, M.

AU - Garuti, F.

AU - Neri, A.

AU - Piscaglia, F.

AU - Lenzi, B.

AU - Valente, M.

AU - Trevisani, F.

AU - Bolondi, L.

AU - Biselli, M.

AU - Caraceni, P.

AU - Cucchetti, A.

AU - Domenicali, M.

AU - Gramenzi, A.

AU - Magalotti, D.

AU - Serra, C.

AU - Venerandi, L.

AU - Cappelli, A.

AU - Golfieri, R.

AU - Mosconi, C.

AU - Renzulli, M.

AU - Giannini, E.G.

AU - Brunacci, M.

AU - Moscatelli, A.

AU - Pellegatta, G.

AU - Savarino, V.

AU - Caturelli, E.

AU - Roselli, P.

AU - Lauria, V.

AU - Pelecca, G.

AU - Dell'Isola, S.

AU - Ialungo, A.M.

AU - Rastrelli, E.

AU - Cabibbo, G.

AU - Cammà, C.

AU - Attardo, S.

AU - Rossi, M.

AU - Rapaccini, G.L.

AU - Gasbarrini, A.

AU - Cavani, G.

AU - Virdone, R.

AU - Affronti, A.

N1 - cited By 0

PY - 2018

Y1 - 2018

N2 - Background:Limited therapies are available for large (≥40 mm) unresectable hepatocellular carcinoma (HCC). Currently, the standard treatment with transarterial chemoembolisation (TACE) is unsatisfactory with high recurrence rate and limited effect on survival. Laser Ablation (LA) has emerged as a relatively new technique characterized by high efficacy and good safety. This study is aimed to evaluate the efficacy of LA in comparison to TACE in patients with large HCC. Methods: Eighty-two patients with a single HCC nodule ≥40 mm (BCLC stage A or B) were enrolled in this case-control study. Forty-one patients were treated with LA and 41 patients were treated with TACE. Response to therapy was evaluated according to the mRECIST criteria. Survival was calculated with Kaplan-Meier from the time of cancer diagnosis to death with values censored at the date of the last follow-up. Results: Twenty-six (63.4%) and 8 (19.5%) patients had a complete response after LA and TACE, respectively (p <0.001). Subsequently we stratified the HCCs in 3 categories according to the nodule size: 40-50 mm, 51-60 mm, and > 60 mm. LA resulted superior to TACE especially in nodules ranging between 51 and 60 mm in diameter, with a complete response rate post-LA and post-TACE of 75% and 14.3%, respectively (p = 0.0133). The 36 months cumulative survival rate in patients treated with LA and TACE was 55.4% and 48.8%, respectively. The disease recurrence rates after LA and TACE were 19.5% and 75.0%, respectively. Conclusions: LA is a more effective therapeutic option than TACE in patients with solitary large HCC. © Morisco et al.

AB - Background:Limited therapies are available for large (≥40 mm) unresectable hepatocellular carcinoma (HCC). Currently, the standard treatment with transarterial chemoembolisation (TACE) is unsatisfactory with high recurrence rate and limited effect on survival. Laser Ablation (LA) has emerged as a relatively new technique characterized by high efficacy and good safety. This study is aimed to evaluate the efficacy of LA in comparison to TACE in patients with large HCC. Methods: Eighty-two patients with a single HCC nodule ≥40 mm (BCLC stage A or B) were enrolled in this case-control study. Forty-one patients were treated with LA and 41 patients were treated with TACE. Response to therapy was evaluated according to the mRECIST criteria. Survival was calculated with Kaplan-Meier from the time of cancer diagnosis to death with values censored at the date of the last follow-up. Results: Twenty-six (63.4%) and 8 (19.5%) patients had a complete response after LA and TACE, respectively (p <0.001). Subsequently we stratified the HCCs in 3 categories according to the nodule size: 40-50 mm, 51-60 mm, and > 60 mm. LA resulted superior to TACE especially in nodules ranging between 51 and 60 mm in diameter, with a complete response rate post-LA and post-TACE of 75% and 14.3%, respectively (p = 0.0133). The 36 months cumulative survival rate in patients treated with LA and TACE was 55.4% and 48.8%, respectively. The disease recurrence rates after LA and TACE were 19.5% and 75.0%, respectively. Conclusions: LA is a more effective therapeutic option than TACE in patients with solitary large HCC. © Morisco et al.

KW - aged

KW - Article

KW - cancer diagnosis

KW - cancer recurrence

KW - cancer survival

KW - case control study

KW - chemoembolization

KW - clinical feature

KW - controlled study

KW - disease free survival

KW - drug efficacy

KW - drug safety

KW - human

KW - Kaplan Meier method

KW - laser surgery

KW - liver cell carcinoma

KW - major clinical study

KW - retrospective study

KW - survival rate

KW - treatment response

KW - univariate analysis

U2 - 10.18632/oncotarget.24756

DO - 10.18632/oncotarget.24756

M3 - Article

VL - 9

SP - 17483

EP - 17490

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 25

ER -